A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer.

Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets.  Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

Schusterman Family Investments

Duquesne Capital Management

The Pags Group

Bristol-Myers Squibb

Cornell University

Ratio Therapeutics

#ICYMI— The recent announcement of our $50M Series B funding round was included in Crunchbase's roundup of the 10 biggest funding rounds of the week. The funding will help us continue to develop our cutting-edge #radiopharmaceuticals for diagnostics and cancer treatment.

https://lnkd.in/e8n3CrFN 

#radiopharma #oncology #funding #innovation

See Ratio featured in this article from Hannah Green of Boston Business Journal, where she interviewed Drs. Jack Hoppin, CEO, and John Babich, CSO, to learn more about how Ratio will use its $50M Series B financing to advance the applications of Ratio’s proprietary #radiopharmaceutical platforms, Trillium and Macropa and support clinical development of its fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic. 

Read here: https://lnkd.in/gBgFSWfZ

#innovation #seriesB #radiopharma

Thank you Kyle LaHucik for interviewing Drs. Jack Hoppin, CEO, and John Babich, CSO, for this Endpoints News article about Ratio’s Series B financing. Ratio raised $50M which will support the development of its #radiopharmaceuticals for treating #cancer, with its first therapeutic candidate targeting fibroblast activation protein-alpha (FAP) to enter the clinic this year.

Read here: https://lnkd.in/eRiUDY78

 #innovation #seriesB #radiopharma

This #WorldCancerDay, let's celebrate the strength and resilience of #cancer survivors and work to reimagine a world where access to life-saving cancer treatments is equitable for all. #CloseTheCareGap

At Ratio, we are committed to developing innovative #radiopharmaceutical therapies that target cancer cells with precision, while minimizing harm to healthy tissue.

Learn more: https://lnkd.in/drnuZeE

Interested in the outlook for the #radiopharmaceuticals space? BioSpace recently published this article predicting rapid growth of the market over the next decade.

Read here: https://lnkd.in/g4RXgJtc 

#biopharma #marketgrowth #cancertreatment

Today, Ratio is pleased to announce the close of a Series B financing bringing the total raised to date to over $90M. Ratio will use the proceeds to advance the development of targeted radiotherapeutics for cancer treatment, including the company’s proprietary technology platforms, Trillium™ and Macropa™ and to drive the clinical development of the company’s fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic.
 
Learn more: https://lnkd.in/emgjYm4M

#radiotherapeutics #biotech #nuclearmedicine #Funding

What's the next big thing in #radiopharmaceuticals?  Get a glimpse into the future with this article in STAT, including our Co-founder and CEO, Jack Hoppin, Ph.D.  

Read the article here: https://lnkd.in/eNG7x_83

#innovation #nuclearmedicine #biotech

#MeetTheTeam – Shawn Hillier, Ph.D., Ratio’s COO, brings a wealth of experience to Ratio, having worked in the industry for 18 years.

Shawn values the diverse backgrounds of Ratio’s team and our passion and commitment to improving the lives of cancer patients.

“Regardless if you're in the lab or in a G&A support function, the focus is on the patient, and the urgency to bring new radiopharmaceuticals to the patients we serve is real. Collaboration is key to an organization’s success and our team works well together with a focus on our mission.”

#innovation #radiopharmaceuticals #biotech

At Ratio Therapeutics, we're dedicated to developing innovative #radiopharmaceutical therapies that target #cancer cells with precision, while minimizing harm to healthy tissue. 

Learn more about our work: https://www.ratiotx.com

#ICYMI – Allison DeAngelis of STAT featured our Cofounders, CEO Jack Hoppin, Ph.D., and CSO John Babich, Ph.D., in this great article giving an overview of the #radiopharmaceutical industry. 

Read here: https://lnkd.in/eNG7x_83

Boulos & Cooper Pharmaceuticals is committed to developing a new class of antibiotics with activity against all drug-resistant bacteria.

Boulos & Cooper Pharmaceuticals

Ratio Therapeutics is a biotechnology company focused on developing antibiotics to combat antimicrobial resistance. The company leverages advanced computational approaches and machine learning algorithms to accelerate the discovery and development of new treatments against drug-resistant bacteria.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 12, 2024 3:44 AM	ac63b2e8
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 12, 2024 10:10 AM	96dc607b
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 12, 2024 3:44 AM	df482a00
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 12, 2024 3:44 AM	7e556109
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:RATIOTX

Ratio Therapeutics